Abstract B31: Characterization of a novel model of prostate cancer metastasis resulting from androgen receptor suppression
Authors: Clinton K. Matson, Peter S. Nelson
Journal: Cancer Research (2016)

Abstract Background: Prostate cancer (PC) is the second leading cause of male cancer-related mortality: 30,000 men die each year from metastatic disease. The Androgen Receptor (AR) may be the earliest known example of a lineage oncogene – a master regulator of prostate cancer cell survival and growth. The AR protein is detectable at all stages of prostate cancer progression and is the primary target of pharmacological agents capable of suppressing AR signaling to extend survival in men with metastatic prostate cancer (mPC). The CYP17 inhibitor Abiraterone, and the 3rd generation AR antagonist, MDV3100 prolong the survival of men with mPC, though cures remain exceeding rare using these agents individually. In order to develop additional therapies to be used in combination with current AR inhibitors, preclinical models that mimic PC progression need to be established. Tissue microarray studies from hormone-naïve, nodal positive, prostate cancer patients revealed a significant down-regulation of AR protein level in matched nodal metastases versus primary tumors. These results suggest that loss of AR or AR activity could play a role in the progression to metastatic disease. Methods: We used a short-hairpin RNA targeting exon 1 of the AR to reduce AR protein in vivo using a doxycycline-inducible system in the non-metastatic AR-positive human prostate cancer cell line 22Rv1. This cell line model, derived from a primary tumor, is castration-resistant and enzalutamide/MDV3100-resistant. We generated xenografts using 22Rv1shARex1 and evaluated tumor growth and propensity for metastatic spread. We profiled transcriptional changes in the context of AR suppression and compared gene expression changes between grafted tumors and sites of metastatic spread. Results: Xenograft studies in NOD-SCID mice revealed that reduction of the AR protein decreased tumor proliferation rates and promoted cancer metastasis. Tumor-bearing mice exposed to continual reduction of the AR developed large liver metastases and had significantly increased disseminated tumor cells in their bone marrow. Furthermore, intratibial and intracardiac injection of 22Rv1shARex1 followed by AR reduction, resulted in an increased formation of metastases. Transcriptional analysis revealed unique signatures between untreated parental 22Rv1 xenografts, tumors with AR reduction, and liver metastases. Genes up-regulated in xenografts following AR reduction, were also up-regulated in patient metastases versus primary tumors including transcripts encoding EGF, HGF, and ZEB2. Discussion: The AR is the primary therapeutic target for mPC. However, a cure for advanced cancer and metastatic disease remains elusive. Reduction of the AR in the 22Rv1 in vivo model mimics disease progression seen in patients. Molecular changes observed during the transformation of localized cancer to metastatic disease in this model may identify new targets to be used in combination with current therapies intent on ablating AR signaling. Citation Format: Clinton K. Matson, Peter S. Nelson. Characterization of a novel model of prostate cancer metastasis resulting from androgen receptor suppression. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Metastasis; 2015 Nov 30-Dec 3; Austin, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(7 Suppl):Abstract nr B31.